[Neuroprotective activity of the proline-containing dipeptide noopept on the model of brain ischemia induced by the middle cerebral artery occlusion].
The influence of noopept (N-phenylacetyl-L-prolylglycine ethyl ester, GVS-111) on the extent of ischemic cortical stroke was investigated in experiments on white mongrel male rats with ischemia induced by a combination of the middle cerebral artery occlusion with ipsilateral common carotid artery ligation. Animals were treated with noopept (0.5 mg/kg, i.p.) according to the following schedule: 15 min and 2, 24, and 48 h after the occlusion. Test rats were decapitated 72 h after occlusion, brains were extracted and frozen, and thin brain slices were stained with 2,3,5-triphenyltetrazolium chloride. The slices were scanned and processed using Auc 1 computer program, which estimates the percentage of damaged area relative to that of the whole ipsilateral hemisphere. The conditions of coagulation the distal segment of middle cerebral artery were selected, which caused necrosis localized in the fronto-parietal and dorso-lateral regions of the brain cortex without any damage of subcortical structures. The extent of the brain damage in control group (treated by saline) was 18.6%, while that in the group treated with noopept was 12.2%, thus demonstrating a decrease in the infarction area by 34.5% (p < 05). The data on noopept efficacy on the model of the extensive ischemic injury of brain cortex show that this drug has good prospects for use in the neuroprotective treatment of stroke.
Gavrilova
S A
SA
Us
K S
KS
Ostrovskaia
R U
RU
Koshelev
V B
VB
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000473:pathology; D002545:Brain Ischemia / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D017536:Carotid Artery, Common; D016893:Carotid Stenosis / Q000150:complications; D002544:Cerebral Infarction / Q000188:drug therapy / Q000473:pathology; D004151:Dipeptides / Q000627:therapeutic use*; D020244:Infarction, Middle Cerebral Artery / Q000150:complications*; D008026:Ligation; D008297:Male; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D051381:Rats
D004151:Dipeptides; D018696:Neuroprotective Agents; C103871:ethyl phenylacetyl-Pro-Gly